Molecular mechanism of the inhibitory effect of KS-5 on bFGF-induced angiogenesis in vitro and in vivo

Cancer Letters

Volumn 263, Issue 1, 2008, Pages 114-121

  Peng, Chieh Yu ^a   Pan, Shiow Lin ^a   Lee, Kuo Hsiung ^b   Bastow, Kenneth F ^b   Teng, Che Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Acridone derivatives; Angiogenesis; Endothelial cells

Indexed keywords

1,7 DIHYDROXY 3 METHOXYACRIDONE; ACRIDONE DERIVATIVE; BASIC FIBROBLAST GROWTH FACTOR; BROXURIDINE; INITIATION FACTOR 4E; KS 5; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG IMPLANTATION; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ACRIDONES; ANGIOGENESIS INHIBITORS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; DNA REPLICATION; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN KINASES;

MUS MUSCULUS;

EID: 41049106522     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.12.028     Document Type: Article

References (32)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 6 (2007) 273-286
2. Bikfalvi A. Angiogenesis: health and disease. Ann. Oncol. 17 (2006) x65-x70
3. Ruhrberg C. Endogenous inhibitors of angiogenesis. J. Cell Sci. 114 (2001) 3215-3216
4. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., and Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16 (2005) 159-178
5. Schmelzle T., and Hall M.N. TOR, a central controller of cell growth. Cell 103 (2000) 253-262
6. Fingar D.C., Salama S., Tsou C., Harlow E., and Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16 (2002) 1472-1487
7. Fingar D.C., Richardson C.J., Tee A.R., Cheatham L., Tsou C., and Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24 (2004) 200-216
8. Raught B., and Gingras A.-C. eIF4E activity is regulated at multiple levels. Int. J. Biochem. Cell Biol. 31 (1999) 43-57
9. Marcotrigiano J., Gingras A.-C., Sonenberg N., and Burley S.K. Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Mol. Cell 3 (1999) 707-716
10. Gingras A.-C., Raught B., Gygi S.P., Niedzwiecka A., Miron M., Burley S.K., Polakiewicz R.D., Wyslouch-Cieszynska A., Aebersold R., and Sonenberg N. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15 (2001) 2852-2864
11. Wang X., Beugnet A., Murakami M., Yamanaka S., and Proud C.G. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol. Cell. Biol. 25 (2005) 2558-2572
12. Belmont P., Bosson J., Godet T., and Tiano M. Acridine and acridone derivatives, anticancer properties and synthetic methods: Where are we now?. Anti-Cancer Agents Med. Chem. 7 (2007) 139-169
13. Lowden C.T., and Bastow K.F. Cell culture replication of herpes simplex virus and or human cytomegalovirus is inhibited by 3,7-dialkoxylated, 1-hydroxyacridone derivatives. Antiviral Res. 59 (2003) 143-154
14. Bastow K.F. New acridone inhibitors of human herpes virus replication. Curr. Drug Targets Infect. Disord. 4 (2004) 323-330
15. Jaffe E.A., Nachman R.L., Becker C.G., and Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52 (1973) 2745-2756
16. Graves J.D., Campbell J.S., and Krebs E.G. Protein serine/threonine kinases of the MAPK cascade. Ann. NY Acad. Sci. 766 (1995) 320-343
17. Brader S., and Eccles S.A. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori. 90 (2004) 2-8
18. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
19. Tanaka K., Abe M., and Sato Y. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis. Jpn. J. Cancer Res. 90 (1999) 647-654
20. Cross M.J., and Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22 (2001) 201-207
21. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W.T., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A.M., and Franklin R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta. 1773 (2007) 1263-1284
22. Davis J.M., Weinstein-Oppenheimer C.R., Steelman L.S., Navolanic P.M., Hu W., Konopleva M., Blagosklonny M.V., and McCubrey J.A. Raf-1 and Bcl-2 induce distinct and common pathways which contribute to breast cancer drug resistance. Clin. Cancer Res. 9 (2003) 1161-1170
23. Deng X., Ruvolo P., Carr B., and May Jr. W.S. Survival function of ERK1/2 as an IL-3 activated, staurosporine-resistant Bcl2 kinases. Proc. Natl. Acad. USA 97 (2000) 1578-1583
24. Deng X., Kornblau S.M., Ruvulo P.P., and May Jr. W.S. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J. Natl. Cancer Inst. Monogr. 28 (2001) 30-37
25. Merrick W.C. Cap-dependent and cap-independent translation in eukaryotic systems. Gene 332 (2004) 1-11
26. Averous J., and Proud C.G. When translation meets transformation: the mTOR story. Oncogene 25 (2006) 6423-6435
27. De Benedetti A., and Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene 23 (2004) 3189-3199
28. Minich W.B., Balasta M.L., Goss D.J., and Rhoads R.E. Chromatographic resolution of in vivo phosphorylated and nonphosphorylated eukaryotic translation initiation factor eIF-4E: increased cap affinity of the phosphorylated form. Proc. Natl. Acad. USA 91 (1994) 7668-7672
29. Wang X., Li W., Parra J.L., Beugnet A., and Proud C.G. The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol. Cell. Biol. 23 (2003) 1546-1557
30. Gingras A.-C., Gygi S.P., Raught B., Polakiewicz R.D., Abraham R.T., Hoekstra M.F., Aebersold R., and Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13 (1999) 1422-1437
31. Seghezzi G., Patel S., Ren C.J., Gualandris A., Pintucci G., Robbins E.S., Shapiro R.L., Galloway A.C., Rifkin D.B., and Mignatti P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis. J. Cell Biol. 141 (1998) 1659-1673
32. Hata Y., Rook S.L., and Aiello L.P. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. Diabetes 48 (1999) 1145-1155